HighGravityDataAmgen — Aug 4, 2026 release
Fiscal 2026 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000318154-26-000124
Showing in the filing
Tax rate (non-GAAP basis)
“15.0% to 16.5%”
Period
FY2026
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 7
Total revenues for FY2026
“$38.2 billion to $39.4 billion”
EPS (GAAP basis) for FY2026
“$15.80 to $17.08”
Tax rate (GAAP basis) for FY2026
“14.5% to 16.0%”
EPS (non-GAAP basis) for FY2026
“$22.30 to $23.50”
Tax rate (non-GAAP basis) for FY2026
“15.0% to 16.5%”
Capital expenditures for FY2026
“approximately $2.6 billion”
Share repurchases for FY2026
“not to exceed $3.0 billion”
Exhibit 99.1 · the passage around this item
… earlier in the release
$Billions, except shares Q2 ’26 Q2 ’25 YOY Δ Operating Cash Flow $ 4.0 $ 2.3 $ 1.7 Capital Expenditures $ 0.5 $ 0.4 $ 0.1 Free Cash Flow $ 3.5 $ 1.9 $ 1.6 Dividends Paid $ 1.4 $ 1.3 $ 0.1 Share Repurchases $ 0.0 $ 0.0 $ 0.0 Average Diluted Shares (millions) 544 541 3 Note: Numbers may not add due to rounding $Billions 6/30/26 12/31/25 YTD Δ Cash and Cash Equivalents $ 14.0 $ 9.1 $ 4.9 Debt Outstanding $ 57.3 $ 54.6 $ 2.7 Note: Numbers may not add due to rounding 2026 Guidance For the full year 2026, the Company expects: • Total revenues in the range of $38.2 billion to $39.4 billion. • On a GAAP basis, EPS in the range of $15.80 to $17.08, and a tax rate in the range of 14.5% to 16.0%. • On a non-GAAP basis, EPS in the range of $22.30 to $23.50, and a tax rate in the range of 15.0% to 16.5%. • Capital expenditures to be approximately $2.6 billion. • Share repurchases not to exceed $3.0 billion. AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Page 7 Second Quarter Product and Pipeline Update The Company provided the following updates on selected product and pipeline programs: General Medicine MariTide (maridebart cafraglutide/AMG 133) • MariTide is a differentiated antibody-peptide conjugate that activates the glucagon-like peptide-1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR). MariTide's long-acting design supports starting with monthly dosing, and staying on MariTide with as few as 4 or 6 doses per year. • MARITIME-1, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, without Type 2 diabetes (T2D). • MARITIME-2, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, with T2D. • MARITIME-CV, a Phase 3 study of MariTide on cardiovascular (CV) outcomes, is enrolling adults living with established atherosclerotic cardiovascular disease and obesity or overweight. • MARITIME-HF, a Phase 3 stud
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.